Article Information
History
- October 14, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Karan Pattni1,
- Daniel Hungerford2,
- Sarah Adams3,
- Iain Buchan4,
- Christopher P Cheyne5,
- Marta García-Fiñana5,
- Ian Hall6,7,
- David M Hughes5,
- Christopher Overton6,
- Xingna Zhang3 and
- Kieran J. Sharkey1,*
- 1Department of Mathematical Sciences, University of Liverpool
- 2Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool
- 3Graphnet Health
- 4Institute of Population Health, University of Liverpool
- 5Department of Health Data Science, University of Liverpool
- 6Department of Mathematics and School of Health Sciences, University of Manchester
- 7Joint Universities Pandemic and Epidemiological Research, UK
- ↵*Corresponding Author: Kieran J. Sharkey, Department of Mathematical Sciences, University of Liverpool; +44 (0)151 794 4023 — kjs{at}liverpool.ac.uk
Posted October 14, 2021.
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
